SCHEDULE 13G/A: T. Rowe Price Associates Discloses 7.2% Passive Stake in Bio-Techne Corp
Beneficial Ownership Statement
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 7.2% beneficial ownership stake in Bio-Techne Corp's common stock as of March 31, 2025.
Summary
- T. Rowe Price Associates, Inc. reported beneficial ownership of 11,383,607 shares of Bio-Techne Corp's common stock.
- This ownership represents 7.2% of the total class of securities.
- T. Rowe Price Associates holds sole voting power over 10,995,222 shares.
- T. Rowe Price Associates holds sole dispositive power over 11,374,793 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported passive investment position.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Bio-Techne Corp.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake. While it doesn't contain explicit positive or negative news, the presence of a significant institutional investor like T. Rowe Price can be viewed as a neutral to slightly positive signal of confidence in the company.
Positives
- The disclosure of a significant stake by a major institutional investor like T. Rowe Price Associates can be viewed as a vote of confidence in Bio-Techne Corp's long-term prospects.
- The passive nature of the investment (Schedule 13G filing) suggests T. Rowe Price is not seeking to influence management or control, which can be seen as a stable, long-term holding.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding Bio-Techne Corp's future performance or T. Rowe Price's investment strategy beyond the current beneficial ownership.
Industry Context
T. Rowe Price Associates is a globally recognized investment management firm. Their significant stake in Bio-Techne Corp, a company operating in the life sciences and diagnostics industry, reflects ongoing institutional interest in the sector. Such passive investments by large asset managers are common and indicate a belief in the company's market position and growth potential within its industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant, passive stake by a reputable institutional investor may reassure existing shareholders and potentially attract new investors, signaling institutional confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement (beneficial ownership calculation date). |
| 05/14/2025 | Date the Schedule 13G/A was signed and filed. |
Keywords
Bio-Techne Corp, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.